
Zydus Wellness (ZYDUSWELL) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
8.6B
Gross Profit
4.7B
54.79%
Operating Income
1.4B
16.85%
Net Income
1.3B
14.91%
EPS (Diluted)
₹20.10
Balance Sheet Metrics
Total Assets
64.4B
Total Liabilities
7.7B
Shareholders Equity
56.7B
Debt to Equity
0.14
Cash Flow Metrics
Revenue & Profitability Trend
Zydus Wellness Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 26.9B | 23.2B | 22.4B | 19.9B | 18.5B |
Cost of Goods Sold | 12.9B | 11.5B | 11.5B | 9.9B | 8.5B |
Gross Profit | 14.0B | 11.7B | 10.9B | 10.0B | 10.0B |
Gross Margin % | 52.2% | 50.5% | 48.6% | 50.4% | 54.1% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 6.2B | 5.1B | 4.4B | 3.9B | 3.8B |
Other Operating Expenses | 1.3B | 1.2B | 1.1B | 879.8M | 889.1M |
Total Operating Expenses | 7.5B | 6.3B | 5.6B | 4.8B | 4.7B |
Operating Income | 8.3B | 2.8B | 3.1B | 3.2B | 3.2B |
Operating Margin % | 30.7% | 12.3% | 13.9% | 16.1% | 17.2% |
Non-Operating Items | |||||
Interest Income | 31.0M | 110.0M | 32.0M | 92.9M | 67.6M |
Interest Expense | 116.0M | 237.0M | 158.0M | 251.1M | 834.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 3.6B | 2.6B | 2.9B | 3.1B | 1.1B |
Income Tax | 119.0M | -68.0M | -195.0M | -28.5M | -65.2M |
Effective Tax Rate % | 3.3% | -2.6% | -6.7% | -0.9% | -5.8% |
Net Income | 3.5B | 2.7B | 3.1B | 3.1B | 1.2B |
Net Margin % | 12.9% | 11.5% | 13.8% | 15.5% | 6.4% |
Key Metrics | |||||
EBITDA | 3.8B | 3.2B | 3.4B | 3.5B | 3.5B |
EPS (Basic) | ₹54.52 | ₹41.94 | ₹48.78 | ₹48.54 | ₹19.55 |
EPS (Diluted) | ₹54.52 | ₹41.94 | ₹48.78 | ₹48.54 | ₹19.55 |
Basic Shares Outstanding | 63632144 | 63632144 | 63632144 | 63632144 | 60741344 |
Diluted Shares Outstanding | 63632144 | 63632144 | 63632144 | 63632144 | 60741344 |
Income Statement Trend
Zydus Wellness Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 667.0M | 800.0M | 370.0M | 1.2B | 1.7B |
Short-term Investments | 425.0M | 2.4B | 706.0M | 808.9M | 783.7M |
Accounts Receivable | 3.7B | 2.8B | 2.1B | 1.4B | 942.8M |
Inventory | 5.2B | 4.7B | 4.6B | 3.6B | 3.6B |
Other Current Assets | 890.0M | 1.1B | 1.1B | 919.1M | 1.2B |
Total Current Assets | 11.0B | 12.1B | 9.1B | 8.1B | 8.5B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.9B | 2.5B | 2.7B | 2.4B | 2.0B |
Goodwill | 88.4B | 83.8B | 83.8B | 83.9B | 83.9B |
Intangible Assets | 8.2B | 5.4B | 5.4B | 5.5B | 5.5B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 414.0M | 111.0M | 168.1M | 170.1M | 117.3M |
Total Non-Current Assets | 53.4B | 49.3B | 49.3B | 48.8B | 48.2B |
Total Assets | 64.4B | 61.5B | 58.3B | 56.9B | 56.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 4.3B | 3.6B | 3.1B | 3.6B | 4.4B |
Short-term Debt | 1.9B | 3.3B | 2.9B | 3.2B | 2.4B |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 497.0M | 361.0M | 386.1M | 344.6M | 469.5M |
Total Current Liabilities | 7.5B | 7.7B | 6.9B | 7.7B | 7.7B |
Non-Current Liabilities | |||||
Long-term Debt | 14.0M | 32.0M | 35.0M | 672.1M | 3.1B |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 4.0M | 7.0M | - | 3.1M | 10.0M |
Total Non-Current Liabilities | 248.0M | 215.0M | 181.0M | 813.4M | 3.3B |
Total Liabilities | 7.7B | 7.9B | 7.1B | 8.5B | 11.0B |
Equity | |||||
Common Stock | 636.0M | 636.0M | 636.0M | 636.3M | 636.3M |
Retained Earnings | 20.3B | 17.1B | 14.8B | 12.0B | 9.2B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 56.7B | 53.6B | 51.2B | 48.4B | 45.7B |
Key Metrics | |||||
Total Debt | 1.9B | 3.3B | 3.0B | 3.9B | 5.5B |
Working Capital | 3.6B | 4.4B | 2.2B | 468.9M | 759.7M |
Balance Sheet Composition
Zydus Wellness Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 3.6B | 2.6B | 2.9B | 3.1B | 1.1B |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -781.0M | -923.0M | -1.9B | -363.9M | -655.9M |
Operating Cash Flow | 2.9B | 1.8B | 1.2B | 2.6B | 1.7B |
Investing Activities | |||||
Capital Expenditures | -653.0M | -264.0M | -444.0M | -747.3M | -174.6M |
Acquisitions | -3.7B | -7.0M | 0 | 0 | 0 |
Investment Purchases | 0 | -51.0M | -414.0M | -259.1M | -18.9M |
Investment Sales | 2.1B | 4.0M | 1.0M | 54.0M | 21.8M |
Investing Cash Flow | -2.3B | -318.0M | -857.0M | -952.4M | -171.7M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -318.0M | -319.0M | -319.0M | -318.8M | -1.9M |
Debt Issuance | - | - | - | 0 | 3.1B |
Debt Repayment | 0 | -625.0M | -2.5B | -1.9B | -15.0B |
Financing Cash Flow | -1.7B | -4.0M | -1.2B | -2.0B | -1.2B |
Free Cash Flow | 3.1B | 2.2B | 467.0M | 1.6B | 2.7B |
Net Change in Cash | -1.1B | 1.5B | -904.0M | -353.2M | 394.9M |
Cash Flow Trend
Zydus Wellness Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
37.51
Forward P/E
24.74
Price to Book
2.17
Price to Sales
4.50
PEG Ratio
-2.80
Profitability Ratios
Profit Margin
11.99%
Operating Margin
16.79%
Return on Equity
6.12%
Return on Assets
5.39%
Financial Health
Current Ratio
1.48
Debt to Equity
3.32
Beta
-0.23
Per Share Data
EPS (TTM)
₹51.45
Book Value per Share
₹891.31
Revenue per Share
₹428.85
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
zyduswell | 122.8B | 37.51 | 2.17 | 6.12% | 11.99% | 3.32 |
Nestle India | 2.1T | 67.58 | 52.39 | 79.99% | 15.21% | 29.11 |
Britannia Industries | 1.3T | 58.14 | 29.32 | 49.73% | 12.02% | 28.45 |
Hatsun Agro Product | 196.0B | 68.96 | 11.42 | 16.23% | 3.18% | 149.66 |
Bikaji Foods | 181.1B | 89.27 | 13.07 | 13.57% | 7.49% | 15.60 |
LT Foods | 154.9B | 24.94 | 4.02 | 15.71% | 6.74% | 32.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.